Follow our publications on the evolving outbreak of monkeypox Read the articles in our collection
Food as a vehicle for antimicrobial resistance: submit your articles that fit our annual theme
Check the details hereCoronavirus disease 2019 (COVID-19) Take a look at our collection
Eurosurveillance: 1996 to 2021
25 years of public health impact Explore our anniversary collectionLooking at the benefits and risks, efficacy and vaccine effectiveness
Find them in our COVID-19 vaccines collection
Eurosurveillance
Since 1995, Eurosurveillance has provided the European public health community with an open-access platform to exchange relevant findings on communicable disease surveillance, prevention and control. A weekly, electronic, peer-reviewed publication, Eurosurveillance aims to provide timely facts and guidance for public health professionals and decision-makers in the field of infectious disease to facilitate the implementation of effective prevention and control measures. Impact factor: 6.3. More...
Latest Issue: Volume 27, Issue 26, 30 June 2022 Latest Issue RSS feed
- Rapid communication
-
-
-
Evidence of surface contamination in hospital rooms occupied by patients infected with monkeypox, Germany, June 2022
The extent of monkeypox virus environmental contamination of surfaces is unclear. We examined surfaces in rooms occupied by two monkeypox patients on their fourth hospitalisation day. Contamination with up to 105 viral copies/cm2 on inanimate surfaces was estimated by PCR and the virus was successfully isolated from surfaces with more than 106 copies. These data highlight the importance of strict adherence of hospital staff to recommended protective measures. If appropriate, pre-exposure or early post-exposure vaccination should be considered for individuals at risk.
-
-
-
Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22
Compared with individuals unvaccinated in the current and three previous influenza seasons, in 2021/22, influenza vaccine effectiveness at primary care level was 37% (95% CI: 16 to 52) for current season vaccination, regardless of previous doses, and 35% (95% CI: −3 to 45) for only previous seasons vaccination. Against influenza A(H3N2), estimates were 39% (95% CI: 16 to 55) and 24% (95% CI: −8 to 47) suggesting moderate effectiveness of current season vaccination and possible remaining effect of prior vaccinations.
-
- Top
-
- Euroroundup
-
-
-
Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned
Jayshree Bagaria , Tessa Jansen , Diogo FP Marques , Mariette Hooiveld , Jim McMenamin , Simon de Lusignan , Ana-Maria Vilcu , Adam Meijer , Ana-Paula Rodrigues , Mia Brytting , Clara Mazagatos , Jade Cogdale , Sylvie van der Werf , Frederika Dijkstra , Raquel Guiomar , Theresa Enkirch , Marta Valenciano and I-MOVE-COVID-19 study teamAs the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March–September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced.
-
- Top
-
- Research
-
-
-
A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
BackgroundThere is a paucity of data on community-based Clostridioides difficile infection (CDI) and how these compare with inpatient CDI.
AimTo compare data on the populations with CDI in hospitals vs the community across 12 European countries.
MethodsFor this point-prevalence study (July–November 2018), testing sites sent residual diagnostic material on sampling days to a coordinating laboratory for CDI testing and PCR ribotyping (n = 3,163). Information on whether CDI testing was requested at the original site was used to identify undiagnosed CDI. We used medical records to identify differences between healthcare settings in patient demographics and risk factors for detection of C. difficile with or without free toxin.
ResultsThe CDI positivity rate was 4.4% (country range: 0–16.2) in hospital samples, and 1.3% (country range: 0–2.2%) in community samples. The highest prevalence of toxinotype IIIb (027, 181 and 176) was seen in eastern European countries (56%; 43/77), the region with the lowest testing rate (58%; 164/281). Different predisposing risk factors were observed (use of broad-spectrum penicillins in the community (OR: 8.09 (1.9–35.6), p = 0.01); fluoroquinolones/cephalosporins in hospitals (OR: 2.2 (1.2–4.3), p = 0.01; OR: 2.0 (1.1–3.7), p = 0.02)). Half of community CDI cases were undetected because of absence of clinical suspicion, accounting for three times more undiagnosed adults in the community compared with hospitals (ca 111,000 vs 37,000 cases/year in Europe).
ConclusionThese findings support recommendations for improving diagnosis in patients presenting with diarrhoea in the community, to guide good practice to limit the spread of CDI.
-
-
Recent articles
-
-
One Health surveillance of West Nile and Usutu viruses: a repeated cross-sectional study exploring seroprevalence and endemicity in Southern France, 2016 to 2020
Orianne Constant , Patricia Gil , Jonathan Barthelemy , Karine Bolloré , Vincent Foulongne , Caroline Desmetz , Agnès Leblond , Isabelle Desjardins , Sophie Pradier , Aurélien Joulié , Alain Sandoz , Rayane Amaral , Michel Boisseau , Ignace Rakotoarivony , Thierry Baldet , Albane Marie , Benoît Frances , Florence Reboul Salze , Bachirou Tinto , Philippe Van de Perre , Sara Salinas , Cécile Beck , Sylvie Lecolinet , Serafin Gutierrez and Yannick Simonin
-
-
-
-
- More Less